Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients
Status:
Recruiting
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
Diabetes Mellitus is the leading cause of end stage renal disease. As proven by many studies
, controlling proteinuria can delay the progression to end stage renal disease.This work will
study the effect of sodium glucose co transporter 2 inhibitor , a new antihyperglycemic drug
, on proteinuria and to compare its effect with the effect of classic antiproteinuric drugs
as angiotensin converting enzyme inhibitor , aspirin and statins.